<DOC>
	<DOCNO>NCT00226980</DOCNO>
	<brief_summary>The purpose study determine efficacy combination thalidomide capecitabine metastatic renal cell carcinoma also determine safety combination .</brief_summary>
	<brief_title>A Trial Thalidomide Capecitabine Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Able comprehend sign IRB approve Informed consent Willingness ability comply FDAmandated S.T.E.P.S.Â® program . Male female 18 year old Willing use contraception Pathologic diagnosis renal cell carcinoma Bidimensionally measurable disease Evidence disease progression prior start treatment Failed prior immunotherapy unwilling/unable receive prior immunotherapy Adequate hematologic data : ANC.1.5 ; platelet &gt; 100x10^9 Adequate renal function : Creatinine clearance .50cc Adequate liver function : Alkaline phos &lt; 3XULN AST/ALT &lt; 3XULN T.Bili &lt; 1.5XULN ECOG performance status 01 Known brain metastasis . Peripheral neuropathy . Pregnant and/ lactate female . Unable take baby aspirin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>